|Articles|January 13, 2020

Ergomed Acquires Ashfield Pharmacovigilance Inc.

Ergomed plc has announced the acquisition of Ashfield Pharmacovigilance Inc. from UDG Healthcare US Holdings, Inc. Ergomed has acquired the entire issued share capital of Ashfield PV for a total cash consideration of $10 million.

For more information, click here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Ergomed Acquires Ashfield Pharmacovigilance Inc.

Newsletter

Related Content

Reducing Site Burden Through Better Technology Integration in Clinical Trials

Broad Survival Benefit from MATTERHORN Trial Highlights New Approach to Biomarker Use

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials

Trending on Applied Clinical Trials Online

Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer

Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development

Reducing Site Burden Through Better Technology Integration in Clinical Trials

ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen

Broad Survival Benefit from MATTERHORN Trial Highlights New Approach to Biomarker Use